Welcome to our dedicated page for Pmv Pharmaceuticals news (Ticker: PMVP), a resource for investors and traders seeking the latest updates and insights on Pmv Pharmaceuticals stock.
PMV Pharmaceuticals reports news as a precision oncology company developing small molecule therapies that target p53. Its recurring updates center on rezatapopt, an oral product candidate designed to reactivate mutant p53 in tumors with the TP53 Y220C mutation, and on the PYNNACLE clinical trial in advanced solid tumors, including ovarian cancer.
Company announcements also cover clinical data presentations and publications, FDA designation activity, periodic financial results, research and development spending tied to rezatapopt, cash runway commentary, and board governance changes.
PMV Pharmaceuticals has announced the pricing of its initial public offering (IPO) of 11,765,000 shares at $18.00 per share, aiming to raise approximately $211.8 million before expenses. The IPO is set to begin trading on the Nasdaq under the ticker symbol PMVP on September 25, 2020, with the offering expected to close on September 29, 2020. The underwriters have a 30-day option to purchase an additional 1,764,750 shares at the IPO price. Key financial firms are managing the offering, and a registration statement has been filed with the SEC.